|
Based on the information provided, no conclusions can be made.As reported, patient experienced post-op complication of seroma.Medical affairs has assessed the patient¿s postoperative course as being serious and likely related to the study device.Review of the device history records confirmed the device was manufactured to specification.Seroma is known inherent risk of the surgery/use of the device and included as a possible complication in the adverse reaction section of the instruction for use (ifu) supplied with the device.This mdr is being submitted to report the galaflex 3dr (device #2); an additional mdr shall be submitted to report the galaflex (device #1).Note: this mdr report is related to a retrospective study conducted to proactively gather real-world evidence on the use and safety of the p4hb product family, including galaflex scaffold, galaflex 3d, and galaflex 3dr. all safety events from the study are adjudicated by the bd medical monitor for an independent assessment of severity and relatedness. in an abundance of caution, events for which relatedness cannot be ruled out are processed for mdr reporting.Not returned - remains implanted.
|
|
Per clinical trial (b)(4): on (b)(6) 2018, patient underwent bilateral augmentation mastopexy using a vertical incision.1 piece of galaflex (device #1) and 2 pieces of galaform (galaflex 3dr) (device #2) were used.Concomitant procedure was capsulorrhaphy.On (b)(6) 2018, left breast seroma was reported.Patient treated with serosanguinous fluid aspirations over several days and placement of a seroma catheter.Also treated with medication (cipro).Drain removed (b)(6) 2018.Resolved (b)(6) 2018 without sequelae.Review by medical affairs identifies the reported seroma is likely related to the device and serious.
|